Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
The FDA May Decide on Novavax's Vaccine Next Week: Here's What You Need to Know
10:00am, Thursday, 02'nd Jun 2022 The Motley Fool
Could this be the share-price catalyst that investors have been waiting for?
Pfizer asks FDA to authorize its 3-dose COVID vaccine for children under 5
10:34pm, Wednesday, 01'st Jun 2022 MarketWatch
The companies said last month that three doses of the shot were 80% effective at preventing symptomatic COVID-19 and generated a robust immune response in children ages 6 months to 5 years old.
Here's Why Pfizer's COVID Revenue Could Remain Strong Next Year
02:15pm, Wednesday, 01'st Jun 2022 The Motley Fool
The company has multiple ways it can still generate meaningful COVID revenue in 2023.
Don't fall in love with stocks, they'll break your heart
02:10pm, Tuesday, 31'st May 2022 MarketWatch
Sexy stocks may bring an initial thrill, but when it comes to investing, boring is usually best.
The Zacks Analyst Blog Highlights AstraZeneca, Merck, Roche, J&J, and Pfizer
01:39pm, Tuesday, 31'st May 2022 Zacks Investment Research
AstraZeneca, Merck, Roche, J&J, and Pfizer are part of Zacks top Analyst Blog
Better COVID Stock: Pfizer vs. Moderna
10:00am, Tuesday, 31'st May 2022 The Motley Fool
They both dominate the vaccine market today.
A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?
12:58pm, Sunday, 29'th May 2022 MarketWatch
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
3 Dividend Stocks You Can Buy and Hold Forever
11:31am, Sunday, 29'th May 2022 The Motley Fool
Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.
Will This Beaten-Down Stock Bounce Back? 3 Things to Know
10:30am, Saturday, 28'th May 2022 The Motley Fool
Ocugen shares soared when it first entered the coronavirus vaccine race.
Why Novavax Is Up More Than 18% Today
06:51pm, Friday, 27'th May 2022 The Motley Fool
The COVID-19 pandemic is still with us, but the effort to end it is starting a new chapter.
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
05:34pm, Friday, 27'th May 2022 Zacks Investment Research
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
White House steps up effort to get antiviral access to more Americans as cases start to stabilize in Northeast
02:23pm, Friday, 27'th May 2022 MarketWatch
The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S., cautioning that COVID-19 cases are likely to continue to climb over the summe
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
01:29pm, Friday, 27'th May 2022 Zacks Investment Research
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
The FDA's decision on the Novavax COVID-19 vaccine could come in weeks
11:48am, Friday, 27'th May 2022 MarketWatch
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
Why Novavax Was Tumbling by 12% This Week
11:13pm, Thursday, 26'th May 2022 The Motley Fool
Outshined by rival coronavirus vaccine developers, the stock is hit with a downbeat analyst report from a prominent bank.
